Your browser doesn't support javascript.
loading
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.
Morris, Michael J; Loriot, Yohann; Sweeney, Christopher J; Fizazi, Karim; Ryan, Charles J; Shevrin, Daniel H; Antonarakis, Emmanuel S; Pandit-Taskar, Neeta; Deandreis, Désirée; Jacene, Heather A; Vesselle, Hubert; Petrenciuc, Oana; Lu, Cindy; Carrasquillo, Jorge A; Higano, Celestia S.
Afiliación
  • Morris MJ; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY, USA. Electronic address: morrism@mskcc.org.
  • Loriot Y; Department of Cancer Medicine, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Sweeney CJ; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Fizazi K; Department of Cancer Medicine, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Ryan CJ; Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
  • Shevrin DH; NorthShore Medical Group, NorthShore University Health System, Evanston Hospital Kellogg Cancer Center, Evanston, IL, USA.
  • Antonarakis ES; The Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • Pandit-Taskar N; Department of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Deandreis D; Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
  • Jacene HA; Department of Imaging, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Vesselle H; Division of Nuclear Medicine, Department of Radiology, University of Washington, Seattle, WA, USA.
  • Petrenciuc O; Department of Global Clinical Development, Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.
  • Lu C; Department of Global Clinical Development, Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.
  • Carrasquillo JA; Department of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Higano CS; Department of Medicine, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Eur J Cancer ; 114: 107-116, 2019 06.
Article en En | MEDLINE | ID: mdl-31082669
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Óseas / Protocolos de Quimioterapia Combinada Antineoplásica / Radio (Elemento) / Neoplasias de la Próstata Resistentes a la Castración / Docetaxel Tipo de estudio: Clinical_trials Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Año: 2019 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Óseas / Protocolos de Quimioterapia Combinada Antineoplásica / Radio (Elemento) / Neoplasias de la Próstata Resistentes a la Castración / Docetaxel Tipo de estudio: Clinical_trials Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Año: 2019 Tipo del documento: Article